This article was originally published in The Rose Sheet
Consumers should refrain from using soap and other products containing triclosan and other biocides at home, according to the Federal Institute for Risk Assessment, a new scientific body of the Federal Republic of Germany. Noting consumer products contain only low doses of triclosan insufficient to kill bacterial pathogens, FIRA adds, "When it comes to everyday life, soap and water or conventional cleansing products are quite capable of achieving the same effect." The institute expressed concern over the risk of increasing resistance of microorganisms to the ingredient, and concluded products containing triclosan should only be used in clinics and doctors' offices. Antibacterial resistance associated with triclosan use has been a topic of increasing interest in the U.S. In October, FDA's Nonprescription Drugs Advisory Committee unanimously agreed that makers of non-alcohol-based antimicrobials should be required to demonstrate products' clinical benefit prior to sale (1"The Rose Sheet" Oct. 24, 2005, p. 9)...
You may also be interested in...
Marketers of non-alcohol-based consumer antiseptic products should be required to prove their products provide clinical benefit prior to sale, an FDA advisory panel unanimously agreed Oct. 20
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.